Relapsed Refractory Hematologic Malignancies clinical trials

Explore recruiting relapsed refractory hematologic malignancies clinical trials.

Recruiting relapsed refractory hematologic malignancies studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Hematologic Malignancies trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CAR123 T cell treatment of relapsed/refractory hematologic malignancies.

Czechia

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA)

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic Malignancies

Germany, Poland, Italy, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Relapsed Refractory Hematologic Malignancies trials by city

Relapsed Refractory Hematologic Malignancies in Toronto Relapsed Refractory Hematologic Malignancies in Vancouver Relapsed Refractory Hematologic Malignancies in Montreal Relapsed Refractory Hematologic Malignancies in Calgary Relapsed Refractory Hematologic Malignancies in Edmonton Relapsed Refractory Hematologic Malignancies in Ottawa Relapsed Refractory Hematologic Malignancies in Winnipeg Relapsed Refractory Hematologic Malignancies in Quebec City Relapsed Refractory Hematologic Malignancies in Hamilton Relapsed Refractory Hematologic Malignancies in Kitchener Relapsed Refractory Hematologic Malignancies in London Relapsed Refractory Hematologic Malignancies in Halifax Relapsed Refractory Hematologic Malignancies in New York Relapsed Refractory Hematologic Malignancies in Los Angeles Relapsed Refractory Hematologic Malignancies in Chicago Relapsed Refractory Hematologic Malignancies in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease